cardiometabolic

News

GSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio.

R&D

Read how Jan-Feb '26 offered a revealing cross-section of how R&D is evolving across therapy areas.

News

AstraZeneca is the first company to get FDA approval for an aldosterone synthase inhibitor for hypertension, ahead of rival Mineralys.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.